23 completed, 9 terminated, 7 recruiting, 7 withdrawn. 28 Phase 1, 26 Phase 2, 5 Phase 3, 1 Early Phase 1.
Follow duvelisib: new trials by email Literature Review of duvelisib trials Research Report on duvelisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 25 | 2026-08-03 | 2026-10-19 |
| A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) Alectinib, Duvelisib - Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2025-08-08 | 2026-05-26 |
| A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib, Gemcitabine, Bendamustine - Lymphoma | Phase 3 | Recruiting | SecuraBio | 124 | 2025-05-19 | 2026-04-06 |
| Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib, Venetoclax - T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 12 | 2025-05-02 | 2026-07-17 |
| (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) Duvelisib - Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Not yet recruiting | Ruijin Hospital | 200 | 2023-10-20 | 2023-10-23 | |
| Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) Duvelisib, Chidamide - Newly Diagnosed Peripheral T-cell Lymphoma | Phase 2 | Recruiting | Liling Zhang | 36 | 2023-05-08 | 2026-05-18 |
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma CC-486 (5-azacitidine), Duvelisib, Romidepsin - Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2022-11-03 | 2022-11-04 | |
| A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors Duvelisib, SG001 - Advanced Solid Tumors | Phase 1 / Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 128 | 2022-09-20 | 2022-08-19 |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy Duvelisib, CAR T-cells - Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia | Phase 1 | Active not recruiting | Washington University School of Medicine | 42 | 2022-02-28 | 2026-09-24 |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2021-11-18 | 2025-12-04 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Biospecimen Collection, Computed Tomography, Duvelisib - Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 38 | 2021-10-21 | 2026-07-31 |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Duvelisib, Docetaxel - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Kartik Sehgal, MD | 26 | 2021-10-14 | 2026-09-29 |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
| Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Nivolumab, Duvelisib - Unresectable Melanoma | Phase 1 / Phase 2 | Terminated | John Kirkwood | 13 | 2021-10-06 | 2025-12-17 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2021-08-12 | 2026-09-09 |
| Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) Duvelisib, Placebo - COVID-19 | Phase 2 | Completed | Emory University | 47 | 2020-11-18 | 2023-04-07 |
| Duvelisib to Combat COVID-19 Duvelisib, Peripheral blood draw, Placebo - COVID-19 | Phase 2 | Completed | Washington University School of Medicine | 28 | 2020-10-12 | 2023-03-06 |
Showing 20 of 55. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma (9) · Lymphoma, Follicular (7) · Lymphoma, T-Cell (7) · Lymphoma, Non-Hodgkin (6) · Recurrence (6) · Leukemia (4) · Lymphoma, T-Cell, Peripheral (4) · Hematologic Neoplasms (3) · Hereditary Sensory and Autonomic Neuropathies (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Large B-Cell, Diffuse (3) · COVID-19 (2) · Enteropathy-Associated T-Cell Lymphoma (2) · Head and Neck Neoplasms (2)
SecuraBio (25) · Memorial Sloan Kettering Cancer Center (3) · Washington University School of Medicine (3) · AbbVie (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · David Bond, MD (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · John Kirkwood (1) · Jonsson Comprehensive Cancer Center (1) · Kartik Sehgal, MD (1)
United States (42) · Italy (9) · United Kingdom (8) · Germany (7) · France (6) · Belgium (5) · Spain (5) · Hungary (4) · Poland (4) · Australia (3) · Czechia (3) · Netherlands (3) · New Zealand (3) · Austria (2) · Bulgaria (2)
Hagop Youssoufian, MD (14) · Alexey V Danilov (1) · Alison Moskowitz, MD (1) · Amanda Cashen, M.D. (1) · Armin Ghobadi, M.D. (1) · Christina Poh (1) · Clare C Sun, M.D. (1) · David Bond, MD (1) · Edmund K Waller, MD, PhD (1) · Edmund Waller, MD, PhD (1) · Hayder Saeed, MD (1) · Ian Flinn, M.D. (1) · John DiPersio, M.D., Ph.D. (1) · John Hayslip, MD (1) · John Kirkwood, MD (1)
PMID 28017967, PMID 29191916, PMID 29233821, PMID 30287523, PMID 30742566, PMID 33786583, PMID 37953814, PMID 38836342, PMID 38886623, PMID 41886642, PMID 42018969, PMID 42545812
2015 (2), 2019 (2), P30CA033572 (2), 2014 (1), P30CA138292 (1), U10CA180821 (1), UM1CA186689 (1)